Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
682.6 INR | -0.31% | -2.72% | +25.07% |
Apr. 17 | Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility | MT |
Feb. 02 | India's Jubilant Pharmova posts quarterly profit | RE |
Sales 2022 | 61.3B 736M | Sales 2023 | 62.82B 754M | Capitalization | 44.42B 533M |
---|---|---|---|---|---|
Net income 2022 | 4.14B 49.7M | Net income 2023 | -610M -7.32M | EV / Sales 2022 | 1.37 x |
Net Debt 2022 | 22.03B 264M | Net Debt 2023 | 26.44B 318M | EV / Sales 2023 | 1.13 x |
P/E ratio 2022 |
14.9
x | P/E ratio 2023 |
-72.8
x | Employees | 5,778 |
Yield 2022 |
1.29% | Yield 2023 |
1.79% | Free-Float | 36.33% |
1 day | -0.31% | ||
1 week | -2.72% | ||
Current month | +20.06% | ||
1 month | +20.40% | ||
3 months | +19.85% | ||
6 months | +106.58% | ||
Current year | +25.07% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 17-05-22 | |
Chief Executive Officer | 37 | 17-05-22 | |
Arvind Chokhany
DFI | Director of Finance/CFO | 52 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 67 | 81-12-31 | |
Chairman | 71 | 78-06-20 | |
Chief Executive Officer | 46 | 17-05-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +2.33% | - | |
0.00% | 117 M€ | +0.18% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 682.6 | -0.31% | 10 440 |
24-04-23 | 684.7 | +0.51% | 30,129 |
24-04-22 | 681.2 | +2.34% | 52,445 |
24-04-19 | 665.6 | -5.13% | 67,295 |
24-04-18 | 701.6 | +4.47% | 93,784 |
Delayed Quote Bombay S.E., April 24, 2024 at 06:00 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+25.07% | 1.31B | |
+25.99% | 672B | |
+25.97% | 570B | |
-5.65% | 360B | |
+16.10% | 321B | |
+8.92% | 300B | |
+6.87% | 217B | |
-9.41% | 204B | |
+5.31% | 199B | |
-9.05% | 149B |
- Stock Market
- Equities
- JUBLPHARMA Stock